Search results for "IGF"

showing 10 items of 68 documents

Characteristics of lysosomal phosphomannosyl-enzyme receptors in the rat heart

1987

The receptor system recognizing mannose 6-phosphate groups of lysosomal enzymes has been characterized, e.g. in fibroblasts and liver cells. The purpose of this study was to demonstrate the presence of a phosphomannosyl receptor system in rat heart muscle. The characterization of receptors was accomplished with beta-N-acetylglucosaminidase (beta-GA) secreted by rat embryo fibroblasts after ammonium chloride stimulation. The receptor binding of ligand enzymes was saturated by adding increasing concentrations of beta-GA and the binding increased linearly when the content of membrane protein was increased. The binding of beta-GA was inhibited by mannose and glucose phosphates, especially manno…

MalePhysiologyReceptors Cytoplasmic and NuclearMannoseReceptors Cell SurfaceBiologyReceptor IGF Type 2Radioligand Assaychemistry.chemical_compoundCell surface receptorPhysiology (medical)LysosomemedicineAnimalsReceptorchemistry.chemical_classificationMannose 6-phosphate receptorMyocardiumRats Inbred StrainsLigand (biochemistry)EndocytosisRatsKineticsmedicine.anatomical_structureEnzymechemistryBiochemistryAlkaline phosphataseLysosomesCardiology and Cardiovascular MedicineBasic Research in Cardiology
researchProduct

Growth hormone replacement therapy prevents sarcopenia by a dual mechanism: improvement of protein balance and of antioxidant defenses.

2013

The aim of our study was to elucidate the role of growth hormone (GH) replacement therapy in three of the main mechanisms involved in sarcopenia: alterations in mitochondrial biogenesis, increase in oxidative stress, and alterations in protein balance. We used young and old Wistar rats that received either placebo or low doses of GH to reach normal insulin-like growth factor-1 values observed in the young group. We found an increase in lean body mass and plasma and hepatic insulin-like growth factor-1 levels in the old animals treated with GH. We also found a lowering of age-associated oxidative damage and an induction of antioxidant enzymes in the skeletal muscle of the treated animals. GH…

Malemedicine.medical_specialtyAgingSarcopeniaIGF-1. Mitochondrial biogenesis Myostatin p70S6KHormone Replacement TherapyMyostatinProtein degradationmedicine.disease_causeAntioxidantsInternal medicineMedicineAnimalsRats WistarMuscle Skeletalbiologybusiness.industryProtein turnoverSkeletal muscleProteinsmedicine.diseaseMitochondria MuscleRatsSomatropinEndocrinologymedicine.anatomical_structureMitochondrial biogenesisSarcopeniaGrowth Hormonebiology.proteinBody CompositionGeriatrics and GerontologybusinessOxidative stressThe journals of gerontology. Series A, Biological sciences and medical sciences
researchProduct

Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hor…

2012

OBJECTIVE: An increased prevalence of hematological abnormalities is reported in acromegaly, but to date no reports about the presence of the Janus Kinase (JAK) 2 mutation in acromegalic patients have been described. DESIGN: We report the complex clinical presentation of the unique case, never described, of acromegaly due to GH-secreting pituitary adenoma associated with JAK2 V617F mutation. RESULTS: The patient shows primary thrombocythemia and myelofibrosis, due to JAK2 V617F mutation, severe visceromegaly and a peculiar clinical course of the disease characterized by discrepant values of GH and IGF-1 during somatostatin analog (SA) treatment despite a significant reduction in pituitary a…

Malemedicine.medical_specialtyTime FactorsEndocrinology Diabetes and MetabolismGrowth hormone receptorAcromegaly HGH IGF-1GastroenterologySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyPituitary adenomahemic and lymphatic diseasesInternal medicineAcromegalymedicineAnimalsHumansPituitary NeoplasmsInsulin-Like Growth Factor IRadiometryMyelofibrosisAgedJanus kinase 2biologyHuman Growth HormonePlatelet Countbusiness.industryJanus Kinase 2medicine.diseaseAcromegaly Growth hormone Insulin-like growth factor-1 Janus kinase 2 Growth hormone receptorEndocrinologyAcromegalyMutationPegvisomantbiology.proteinJanus kinasebusinessVisceromegalyFollow-Up StudiesThrombocythemia Essentialmedicine.drug
researchProduct

MECASERMIN TREATMENT OF A CHILD WITH CONGENITAL HYPERINSULINISM LINKED TO INS-R MUTATION

2017

Objectives: Mecasermin is recombinant human insulin-like growth factor 1 (IGF1) which is approved for the treatment of short stature in children with documented primary IGF1 deficiency. Leprechaunism, also known as Donohue syndrome, is a severe disease, secondary to a severe congenital insulin resistance, with prenatal and neonatal growth retardation, typical dysmorphic features, glycaemic dysregulation characterized by hyperinsulinemia and hyperandrogenism. These patients have a poor prognosis with death in the first year of life. Methods: We describe the case of a 3.5 years child, born at 35,4 weeks, with severe fetal growth restriction (weight 1149 gr; length: 38 cm; cranial circumferenc…

Mecasermin IGF1Leprechaunism Donohue syndrome
researchProduct

TRPA1 channel is a cardiac target of mIGF-1/SIRT1 signaling.

2014

Cardiac overexpression of locally acting muscle-restricted (m)IGF-1 and the consequent downstream activation of NAD+-dependent protein deacetylase sirtuin 1 (SIRT1) trigger potent cardiac antioxidative and antihypertrophic effects. Transient receptor potential (TRP) cation channel A1 (TRPA1) belongs to the TRP ion channel family of molecular detectors of thermal and chemical stimuli that activate sensory neurons to produce pain. Recently, it has been shown that TRPA1 activity influences blood pressure, but the significance of TRPA1 in the cardiovascular system remains elusive. In the present work, using genomic screening in mouse hearts, we found that TRPA1 is a target of mIGF-1/SIRT1 sign…

Member 1PhysiologyTransgeneHeart; Insulin-like growth factor-1; Member 1; Sirtuin 1; Subfamily A; Transient receptor potential cation channelBlood PressurePharmacologymedicine.disease_causeTransient receptor potential channelMiceTransient Receptor Potential ChannelsSirtuin 1Physiology (medical)medicineAnimalsMyocytes CardiacInsulin-Like Growth Factor IPromoter Regions GeneticTRPA1 Cation ChannelbiologySirtuin 1AntagonistIGF-1 SIRT1 TRPA1 micefood and beveragesHeartTransient receptor potential cation channelInsulin-like growth factor-1Subfamily APurinesbiology.proteinProtein deacetylaseAcetanilidesNAD+ kinaseSignal transductionCardiology and Cardiovascular Medicinepsychological phenomena and processesOxidative stressSignal Transduction
researchProduct

Prenatal Clinical Assessment of sFlt-1 (Soluble fms-like Tyrosine Kinase-1)/PlGF (Placental Growth Factor) Ratio as a Diagnostic Tool for Preeclampsi…

2013

Background: Aim of the study was a critical assessment of the clinical validity of the prenatal determination of sFlt-1/PlGF for preeclampsia (PE), pregnancy-induced hypertension (PIH), and proteinuria. Our analysis was based on a specificity of 95 % and a sensitivity of 82 % for the prediction of preeclampsia, as described by Elecsys (Roche). Methods: In this retrospective study the ratio of the prenatal antiangiogenic factor sFlt-1 (soluble fms-like tyrosine kinase-1) to the proangiogenic factor PIGF (placental growth factor) was analyzed using the electrochemiluminescence immunoassay of Elecsys (Roche Diagnostics, Mannheim, Germany) in 173 pregnant women. Sixty-three women with PE, 34 wo…

Placental growth factorGynecologymedicine.medical_specialtyProteinuriabusiness.industryObstetrics and GynecologyIntrauterine growth restrictionmedicine.diseaseGastroenterologyArticlePreeclampsiaBlood pressurePIGFInternal medicineMaternity and Midwiferyembryonic structuresmedicineGestationmedicine.symptombusinessSoluble fms-like tyrosine kinase-1
researchProduct

Imbalance of expression of bFGF and PK1 is associated with defective maturation and antenatal placental insufficiency.

2013

Abstract Objective Defective placental maturation is associated with restricted functional capacity and adverse perinatal fetal outcomes. The aim of the study was a comparative analysis of the role of mRNA expression of various angiogenic factors in placental maturation defects. Study design We examined the mRNA expression patterns of prokineticin 1 (PK1), its receptors (PKRs), basic-fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in tissue from third-trimester placentae that exhibited delayed or accelerated villous maturation. Results The expression of PK1 and PKR2 was elevated in placental tissue exhibiting accelerated maturati…

Placental growth factorVascular Endothelial Growth Factor Amedicine.medical_specialtyPlacenta DiseasesReceptors Peptidemedicine.medical_treatmentPlacentaPregnancy Trimester ThirdPlacental insufficiencyBiologyPregnancy ProteinsReceptors G-Protein-CoupledGastrointestinal Hormoneschemistry.chemical_compoundPregnancyInternal medicinemedicineHumansReceptorPlacenta Growth FactorFetusGrowth factorObstetrics and Gynecologymedicine.diseaseProkineticinVascular endothelial growth factorEndocrinologyReproductive MedicinechemistryPIGFFemaleFibroblast Growth Factor 2Vascular Endothelial Growth Factor Endocrine-Gland-DerivedEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Insulin/IGF-1 Signaling: More than a Metabolic Pathway

2014

Background: Dietary intervention and genetic alterations in gene encoding proteins involved in nutrient-sensing pathways can modulate lifespan, influencing longevity. It depends on under/over-expression of regulatory molecules that lead to different expression of homeostatic genes. Insulin/IGF-1 pathway was associated with longevity and lifespan modulation in model organisms. In humans, a key molecule in this pathway is FOXO3A that acts as a TF on homeostatic genes in response to decreased signaling increasing life span. Interestingly, other genes that increase lifespan interact with FOXO3A such as SIRT1, which modulates the oxidative stress response. Methods: We used meta-analytical and ca…

Settore MED/04 - Patologia GeneraleInsulin/IGF-1 SignalingLongevitySNP
researchProduct

Insulin pathway and its correlation with ageing and longevity

2014

Ageing is unavoidable and leads to the reduction of the ability to adapt to the environment, involving the organism at all levels. Approximately 25% of the overall variation in human lifespan can be attributed to genetic factors, which become more relevant for extreme longevity. A “favourable” genetic background is essential to live longer. Longevity depends on the survival after reproduction and genes that lead to longevity are “survival genes” rather than “longevity genes”. But human population is very heterogeneous because of the different genetic background and different environmental stimuli thus it has not been yet possible to identify a clear panel of biomarkers of ageing and longevi…

Settore MED/04 - Patologia Generaleinsulin/IGF-1 pathway; ageing; longevity; inflammationlongevityageinginflammationinsulin/IGF-1 pathway
researchProduct

MAGNESIUM AND ANABOLIC HORMONES IN OLDER MEN

2011

Optimal nutritional and hormonal statuses are determinants of successful age-ing. The age associated decline in anabolic hormones such as testosterone and insulin-like growth factor 1 (IGF-1) is a strong predictor of metabolic syn-drome, diabetes and mortality in older men. Studies have shown that magne-sium intake affects the secretion of total IGF-1 and increase testosterone bioactivity. This observation suggests that magnesium can be a modulator of the anabolic ⁄ catabolic equilibrium disrupted in the elderly people. However, the relationship between magnesium and anabolic hormones in men has not been investigated. We evaluated 399 ‡65-year-old men of CHIANTI in a study population repres…

Settore MED/09 - Medicina Internamagnesium anabolic hormones IGF-1 aging
researchProduct